Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release bupropion versus venlafaxine and placebo in major depressive disorder
2004-003803-19Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupropion in major depressive disorder (MDD) (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in the Montgomery–Åsberg Depression Rating Scale (MADRS). Started Oct 2004; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-003803-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003803-19.